NTH2 Antibody

What is NRF2 and why is it important in cellular research?

NRF2 (Nuclear Factor Erythroid 2-Related Factor 2) functions as a critical transcription factor that regulates cellular responses to oxidative stress and inflammation. It plays a protective role in various pathological conditions including lung, liver, eye, gastrointestinal, metabolic, neurodegenerative, and autoimmune diseases . Molecules that stabilize NRF2 in cells and promote its transcriptional activity have been intensively investigated as potential therapeutic agents for these conditions . Detecting NRF2 accurately is essential for understanding its biology and evaluating the potential druggability of its pathway, making specific and sensitive antibodies crucial research tools .

What challenges are associated with NRF2 detection via antibodies?

The detection of NRF2 presents several significant challenges that researchers must address. First, commercially available anti-NRF2 antibodies often demonstrate low specificity and sensitivity, creating difficulties in accurate detection . Second, NRF2 exists at relatively low abundance in cells under steady-state conditions, further complicating its detection . Third, NRF2 exhibits aberrant migration in SDS-PAGE, moving at approximately 100 kDa despite its predicted molecular weight of ~66 kDa (calculated from its 605 amino acids) . These factors collectively make NRF2 detection in western blot particularly challenging and require careful experimental design and validation .

How does NRF2 migrate in SDS-PAGE and what implications does this have?

Despite having a predicted molecular weight of approximately 66 kDa (based on its 605 amino acids), NRF2 migrates aberrantly in Tris-glycine SDS-PAGE, appearing at around 100 kDa . In 8% Tris-glycine gels, monoclonal anti-NRF2 antibodies typically detect NRF2 as three distinct bands migrating between 100 and 130 kDa . This migration pattern varies depending on the percentage of the gel used . The aberrant migration has been known since the discovery of NRF2 and requires researchers to look for the protein at positions that do not align with its calculated molecular weight . When designing experiments, researchers should use appropriate positive controls and consider using 8% Tris-glycine gels when attempting to resolve the different NRF2 forms.

How can researchers differentiate between true NRF2 signal and non-specific binding in Western blots?

Differentiating between true NRF2 signal and non-specific binding requires multiple validation approaches. Research has shown that certain anti-NRF2 antibodies detect both NRF2 and calmegin, an ER-residing chaperone that co-migrates with NRF2 in SDS-PAGE and often produces a stronger signal in western blots . To distinguish between these signals, researchers should:

• Perform knockdown experiments using NRF2-targeting siRNAs to confirm band identity

• Analyze protein stability through translation inhibition experiments (e.g., with emetine), as NRF2 degrades rapidly while calmegin remains stable for longer periods

• Examine nuclear translocation upon NRF2 activation, as true NRF2 will translocate to the nucleus while calmegin remains cytoplasmic

• Use Cell Signaling Technology clone E5F1, which demonstrates higher specificity for NRF2 in western blot applications

• Consider lambda phosphatase treatment to identify phosphorylated versus non-phosphorylated NRF2 species

What techniques can help distinguish between phosphorylated and non-phosphorylated forms of NRF2?

Distinguishing between phosphorylated and non-phosphorylated forms of NRF2 is critical for understanding its regulatory mechanisms. Research has demonstrated that in 8% Tris-glycine SDS-PAGE gels, NRF2 appears as three distinct bands between 100-130 kDa . Lambda phosphatase treatment experiments reveal that the top band represents phosphorylated NRF2, which upon dephosphorylation is reduced in mass to the middle band (dephosphorylated NRF2) .

The methodological approach for this distinction includes:

• Treating cell lysates with lambda phosphatase

• Comparing treated and untreated samples side-by-side in western blots

• Using monoclonal antibodies that recognize different NRF2 epitopes (such as EP1808Y from Abcam and D1Z9C from Cell Signaling) to confirm the pattern

• Noting that the bottom band (~105 kDa) is not affected by phosphatase treatment and likely represents calmegin rather than NRF2

What are the best practices for detecting nuclear translocation of NRF2 via immunofluorescence?

Detection of nuclear translocation of NRF2 via immunofluorescence requires careful antibody selection and protocol optimization. Research indicates that while many anti-NRF2 antibodies bind to calmegin in western blots, they can still be useful for immunofluorescence detection of nuclear NRF2 but require proper validation . Recommended practices include:

• Use of Cell Signaling E5F1A antibody, which demonstrates high specificity for nuclear NRF2 in immunofluorescence

• Implementation of tyramide-based signal enhancement when using E5F1A, as standard IF procedures may yield signals too weak for detection

• Validation of Abcam EP1808Y antibody results with NRF2 knockdown, as this antibody can also detect specific nuclear NRF2 accumulation despite binding calmegin in western blot

• Treatment with NRF2 activators (e.g., tert-BHQ) as a positive control to confirm nuclear accumulation

• Comparison of results in cells with and without NRF2 knockdown to confirm specificity

How can mass spectrometry validate anti-NRF2 antibody specificity?

Mass spectrometry provides a powerful approach for validating antibody specificity and identifying cross-reactive proteins. The methodological workflow for using LC-MS/MS to validate anti-NRF2 antibody specificity includes:

• Immunoprecipitation of NRF2 under different experimental conditions:

  • Control cells (steady state)

  • Cells treated with NRF2 activators (e.g., tert-BHQ)

  • Cells with inhibited protein translation (e.g., emetine treatment)

• SDS-PAGE separation of immunoprecipitated proteins followed by Flamingo staining and western blot detection

• Excision of gel pieces containing proteins migrating in the 100-130 kDa range, corresponding to NRF2 signal

• In-gel tryptic digestion and LC-MS/MS analysis of the resulting peptides

• Data analysis using appropriate software (e.g., Skyline) to extract chromatograms of representative peptides and manual verification

This approach can confirm the presence of NRF2 peptides in untreated cells and cells treated with NRF2 activators, while revealing their absence in samples where translation is inhibited (where the 105 kDa band recognized by some anti-NRF2 antibodies persists) . Additionally, it can identify cross-reactive proteins like calmegin that might confound western blot analysis .

What controls are essential when evaluating anti-NRF2 antibody specificity?

When evaluating anti-NRF2 antibody specificity, several critical controls should be implemented:

• NRF2 Knockdown Controls: Use siRNA or shRNA to reduce NRF2 expression, allowing identification of bands that represent true NRF2 signal versus non-specific binding . A pool of NRF2-targeting siRNAs can help confirm which bands disappear upon knockdown .

• NRF2 Activation Controls: Treat cells with known NRF2 activators such as tert-butylhydroquinone (tert-BHQ) to induce NRF2 stabilization and nuclear translocation . The top band (phosphorylated NRF2) should accumulate in response to this treatment .

• Translation Inhibition Controls: Treat cells with translation inhibitors like emetine to distinguish between NRF2 (short half-life) and potential cross-reactive proteins like calmegin (longer half-life) . True NRF2 bands should disappear within 2 hours of translation inhibition, while calmegin remains detectable even after 4 hours .

• Phosphatase Treatment Controls: Treat lysates with lambda phosphatase to distinguish between phosphorylated and non-phosphorylated forms of NRF2 . This treatment should convert the top band to the middle band if they represent phosphorylated and non-phosphorylated NRF2, respectively .

• Cellular Fractionation Controls: Separate nuclear and cytoplasmic fractions to confirm that bands representing true NRF2 accumulate in the nuclear fraction upon activator treatment, while cytoplasmic proteins like calmegin remain in the cytoplasmic fraction .

What protocol optimizations improve NRF2 detection in immunoprecipitation experiments?

For optimized immunoprecipitation of NRF2, consider the following methodological adjustments:

• Cell Lysis Conditions: Use a buffer containing 25 mM Tris pH 7.5, 150 mM NaCl, and 0.5% Triton X-100 for effective extraction of NRF2 while maintaining antibody binding capacity .

• Sonication: Apply sonication to lysates to ensure complete cell disruption and release of nuclear proteins like NRF2 .

• Pre-clearing: Pre-clear lysates with beads to reduce non-specific binding before adding anti-NRF2 antibodies .

• Antibody Selection: For immunoprecipitation, use 2 μg of anti-NRF2 antibody (e.g., Abcam clone EP1808Y) per sample of approximately 100 μg total protein .

• Incubation Conditions: Perform immunoprecipitation overnight at optimal temperature to maximize antibody-antigen interaction .

• Bead Selection: Use 50 μl of protein G magnetic beads for efficient pull-down of precipitated NRF2 .

• Washing Protocol: Wash thoroughly with IP buffer followed by PBS to remove non-specifically bound proteins .

• Elution Conditions: Elute in 2x Laemmli buffer at 50°C for 10 minutes to efficiently release bound proteins without excessive denaturation .

• Gel Selection: Separate eluates in 8% SDS-PAGE to achieve optimal resolution of NRF2 bands in the 100-130 kDa range .

What are the most reliable antibody clones for detecting NRF2 in different applications?

Based on current research, the reliability of anti-NRF2 antibody clones varies significantly depending on the application:

When selecting antibodies for NRF2 detection, researchers should consider the specific application, the need for signal enhancement techniques, and the importance of implementing appropriate controls to validate results .

How does NRF2's role in disease contexts impact antibody selection and experimental design?

NRF2's involvement in various disease pathologies necessitates careful consideration of experimental context when selecting antibodies and designing experiments. As a pro-survival and protective factor, NRF2 activation is particularly beneficial in diseases where oxidative stress and inflammation are key pathogenic mechanisms, including lung, liver, eye, gastrointestinal, metabolic, neurodegenerative, and autoimmune diseases .

When studying NRF2 in disease contexts, researchers should:

• Consider Tissue-Specific Expression: Different tissues may express varying levels of NRF2 and potential cross-reactive proteins like calmegin, affecting the signal-to-noise ratio of antibody detection .

• Account for Disease-Associated Modifications: Post-translational modifications of NRF2 may vary in different disease states, potentially affecting antibody binding and necessitating the use of antibodies that recognize different epitopes .

• Validate in Disease-Relevant Models: Confirm antibody specificity in the specific cell types or tissue models relevant to the disease being studied .

• Implement Disease-Specific Controls: Include disease-relevant positive controls, such as known NRF2 activators or inhibitors that mimic disease conditions .

• Consider Therapeutic Implications: When evaluating potential NRF2 pathway modulators as therapeutics, ensure that the antibodies used can reliably detect changes in NRF2 levels and localization in response to these interventions .